Japanese encephalitis is the main cause of viral encephalitis in Asia. In a previous single-arm vaccine trial, an inactivated chromatographically purified Japanese encephalitis Vero cell vaccine (CVI-JE; JEVAC) was safe and immunogenic in 152 Thai children aged 1-3 years receiving a 2-dose primary immunization and booster dose 1 year later. We conducted a 5-year follow-up assessment of the persistence of the immune response the 144 children remaining in this cohort after first booster dose. Immunity was assessed by 50% plaque reduction neutralization test annually for up to 5 years post-booster. Seroprotection rates (95%CI) decreased from 100% (97.1-100) at 1 year post-booster to 93% (85.0-98.3) at 5 years post-booster. No serious vaccine-related adverse events or Japanese encephalitis infections were reported. A 2-dose primary immunization and booster 1 year later with CVI-JE provided long-lasting immunity in the majority of children.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993053PMC
http://dx.doi.org/10.1080/21645515.2022.2028513DOI Listing

Publication Analysis

Top Keywords

japanese encephalitis
16
primary immunization
12
immunization booster
12
inactivated chromatographically
8
chromatographically purified
8
thai children
8
2-dose primary
8
booster dose
8
5 years post-booster
8
encephalitis
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!